Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/Efavirenz in HIV-1-infected patients in western India

MedGenMed Medscape General Medicine

Volumn 10, Issue 8, 2008, Pages

  Pujari, Sanjay ^a   Dravid, Ameet ^a   Gupte, Nikhil ^a   Joshi, Kedar ^a   Bele, Vivek ^a  

^a Institute of Infectious Diseases   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; EFAVIRENZ; EMTRICITABINE; GENERIC DRUG; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG TOXICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INDIA; MALE; MIDDLE AGED; PREVALENCE; STATISTICS; TREATMENT OUTCOME;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; DRUGS, GENERIC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSION; INDIA; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREVALENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 54749105503     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Kumarasamy N, Solomon S, Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis. 2005;41:1525-1528.
3. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29-34.
4. Pujari S, Patel A, Eknath N, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr. 2004;37:1566-1569.
5. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005;39:199-202.
6. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
7. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access. Available at: www.who.int Accessed October 17, 2007.
8. Mathaiss AA, Hinkle J, Menning M, et al. Bioequivalence of efavirenz/ emtricitabine/tenofovir disoproxil fumarate single tablet regimen. J Acquir Immune Defic Syndr. July 2007;publish ahead of print [epub ahead of print].
9. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
10. Gallant JE, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3 year randomized trial. JAMA. 2004;292:191-201.
11. Bartlett JA Chen SS, Quinn JB. Comparative efficacy of nucleoside/ nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overvirew. HIV Clin Trials. 2007;8:221-226.
12. Milinkovic A, Martinez E, Lopez S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther. 2007; 12:407-415.
13. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8:164-172.
14. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-1198.
15. Nelson MR, Katalama C, Mortaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273-1281.
16. Patel SM, Zembower TR, Pallela F, et al. Early onset of tenofovir induced renal failure: Case report and review of literature. ScientificWorldJournal. 2007;7:1140-1148.
17. Malik A, Abraham P, Malin N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment- case report and review of literature. J Infect. 2005;51:E61-E65.
18. Goicoechea M, Liu S, Best B, et al. Greater tenofovir associated renal dysfunction decline with protease inhibitor based versus non-nucleoside reverse transcriptase inhibitor based therapy J Infect Dis. 2008; 197:102-108.
19. Margot NA, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 2006;7:442-450.
20. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource limited countries. Clin Infect Dis. 2007;44:453-455.